The incidence of hypoglycaemia in the sitagliptin group (4.9%) was significantly lower than that in the glipizide group (32.0%).
Hüpoglükeemia esinemissagedus oli sitagliptiini grupis (4, 9%) oluliselt madalam kui glipsiidi grupis (32, 0%).